Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors-Reference-Cited by-同舟云学术

Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors

Published:2023-11-15 Issue:12 Volume:14 Page:1673-1681
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Elsayed Mohamed S. A.¹^ORCID,Blake James F.²,Boys Mark L.¹,Brown Eric³,Chapsal Bruno D.¹,Chicarelli Mark J.¹,Cook Adam W.¹,Fell Jay B.¹^ORCID,Fischer John P.¹,Hanson Lauren⁴,Lemieux Christine⁵,Martinson Matthew C.⁴,McCown Joseph⁶,McNulty Oren T.¹,Mejia Macedonio J.¹,Neitzel Nickolas A.⁷^ORCID,Otten Jennifer N.⁶,Rodriguez Martha E.¹,Wilcox Daniel¹,Wong Christina E.¹,Zhou Yeyun⁸,Hinklin Ronald J.¹^ORCID

Affiliation:

1. Medicinal Chemistry, Pfizer-Boulder, Boulder, Colorado 80301, United States

2. Computational Chemistry, Pfizer-Boulder, Boulder, Colorado 80301, United States

3. Pharmacology, Pfizer-Boulder, Boulder, Colorado 80301, United States

4. Enzymology, Pfizer-Boulder, Boulder, Colorado 80301, United States

5. Cellular Biology, Pfizer-Boulder, Boulder, Colorado 80301, United States

6. ADME Sciences, Pfizer-Boulder, Boulder, Colorado 80301, United States

7. DMPK, Pfizer-Boulder, Boulder, Colorado 80301, United States

8. Structural Biology, Pfizer-Boulder, Boulder, Colorado 80301, United States

Publisher

American Chemical Society (ACS)

Subject